<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104264">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01982461</url>
  </required_header>
  <id_info>
    <org_study_id>PSMB102ROS10-01</org_study_id>
    <nct_id>NCT01982461</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Hypercholesterolemia.</brief_title>
  <official_title>A Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Roty F.C. Tablets 10mg Versus Crestor 10mg F.C. Tablets in Patients With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pin Siang Medical Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pin Siang Medical Biotechnology Co., Ltd.</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to assess the efficacy of reducing plasma low-density
      lipoprotein(LDL) cholesterol and safety in two different brand drugs, Roty F.C. Tablets 10mg
      and Crestor 10mg F.C. Tablets in hypercholesterolemia population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The primary efficacy variable will be defined as the percent mean change in LDL-C from baseline to 12 weeks.</measure>
    <time_frame>baseline to week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary efficacy variable will be described as the change of plasma AGE, sRAGE, Gas6 and sAx1.</measure>
    <time_frame>baseline to week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Rosuvastatin tablet 10mg taken once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crestor®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One Crestor® tablet 10mg taken once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>10mg,once daily</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Roty</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crestor®</intervention_name>
    <description>10mg,once daily</description>
    <arm_group_label>Crestor®</arm_group_label>
    <other_name>Rosuvastatin</other_name>
    <other_name>Crestor®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 20 to 85;

          -  LDL - C between 130 mg/dL and 250 mg/dL;

          -  TG &lt; 400 mg/dL;

          -  Who without use of any statin within 2 week prior to the trial;

          -  Informed consent given.

        Exclusion Criteria:

          -  Known hypersensitivity or history of SAE with another HMG-CoA reductase
             inhibitor, in particular any history of myopathy;

          -  Active liver disease/severe hepatic impairment(Child-Pugh C,ALT2×ULN);

          -  Treatment with Cyclosporin or any disallowed drug;

          -  Patients with unstable angina pectoris;

          -  Pregnant, lactating women;

          -  Patients who have severe medical condition(s) that in the view of the Investigator
             prohibits participation in the trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Jen Hung, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tri-Service General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lu-Hsin Lu, M.S.</last_name>
    <phone>886-2-26270255</phone>
    <phone_ext>206</phone_ext>
    <email>flora@twtungda.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>886-2-87923311</phone>
      <phone_ext>10552</phone_ext>
      <email>tsghirb@ndmctsgh.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 6, 2013</lastchanged_date>
  <firstreceived_date>November 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosuvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
